Abstract
Introduction

Therapeutic angiogenesis is the induction of new blood vessels by the delivery of specific growth factors and is a potentially powerful strategy to treat ischemic conditions. Vascular endothelial growth factor-A (VEGF-A) is the most potent and specific angiogenic factor
. VEGF gene therapy using naked DNA or adenoviral vectors has already been investigated in several clinical trials both for ischemic heart and peripheral artery disease. Initial results were positive, but placebo-controlled phase II studies did not confirm clinical efficacy [2] . The major obstacle appears to be the narrow therapeutic window of VEGF gene therapy, so that small increases in vector dose rapidly go from lack of efficacy to toxic effects, such as the growth of haemangiomas [3] [4] [5] [6] [7] .
Because VEGF remains tightly bound to the extracellular matrix and does not diffuse through tissue [8] , the induction of normal or aberrant angiogenesis depends on the level of VEGF expression in the microenvironment around each producing cell, and not on the total dose delivered [9, 10] . Using retrovirally transduced myoblasts with stable VEGF expression in skeletal muscle, we could previously show that even small numbers of cells expressing high VEGF levels within a heterogeneous population always caused angioma growth. However, when homogeneous expression was achieved by implanting clonal populations, in which every cell produced the same amount, a dose-dependent effect of VEGF became apparent, where a wide range of levels induced only normal, stable and functional vessels, whereas angioma growth occurred above a defined threshold level [9] . Although [11] .
These results were obtained in non-ischemic skeletal muscle.
However, in ischemic tissue a variety of endogenous angiogenic pathways are up-regulated and might alter the effects of exogenously delivered growth factors. In this study we investigated, whether long-term controlled VEGF expression by FACS-purified myoblasts could induce safe angiogenesis and prevent aberrant vascular growth in a rat model of chronic hind limb ischemia.
Materials and methods
Retrovirus production
A truncated version of the rat CD8a gene (tr.rCD8a) was generated by PCR from the full-length transcript (NCBI accession number NM_031538).
Primers were designed to amplify a fragment of rat CD8a spanning codons -ACG CGT ATG AAC TTT CTG  CTC TCT TGG GTG C-3Ј, VEGF-RV: 5Ј-TTT TGC GGC CGC TCA CCG CCT TGG CTT-3Ј. Total RNA was extracted from rat thymus and kidney using an RNeasy kit (QIAgen, Basel, Switzerland) . After retro transcription of 1 g of RNA, the tr.rCD8a fragment and the rat VEGF164 cDNA were generated by PCR according to these conditions: [12] .
Cell culture
Primary myoblasts isolated from C57BL/6 mice and transduced to express the ␤-galactosidase marker gene (lacZ) from a retroviral promoter [13] were further transduced at high efficiency with the pAMFG-rVICD8 retrovirus through four rounds of infection, according to a previously published protocol [14] . Negative 
Myoblast injection in SCID mice
Blood flow determination
Regional blood flow in the hind limb was determined by radioactive microsphere injection, as previously described [16, 18] 
Tissue staining
The entire vascular network of the ear could be visualized after intravascular staining with a biotinylated Lycopersicon esculentum (tomato) lectin (Vector Laboratories, Burlingame, CA, USA) that binds the luminal surface of all blood vessels, as previously described [9] . Briefly [13] . Immunofluorescence on 10 m sections was performed as previously described [9] . Fig. 1D ). Fig. 2D ), similar to those caused by the unsorted population (Fig. 2B) 
Results
Generation of rVICD8 myoblasts
FACS sorting for homogeneous VEGF expression
Chronic hind limb ischemia
Bilateral ligation of the femoral artery was performed in nude rats as depicted in Figure 3A . In order to confirm that induced ischemia was chronic, maximum blood flow in the thigh and calf muscles of non-treated animals were measured before ligation and at 1 and 5 weeks after ligation. No animals developed toe or foot necrosis. Maximum blood flow in the quadriceps muscle was reduced from 181 Ϯ 11 to 141 Ϯ 14 ml/min./100 g and remained at 137 Ϯ 11 ml/min./100 g after 5 weeks (P Ͻ 0.05, Fig. 3B) . Similarly, maximum blood flow in the medial hamstring muscle was reduced from 124 Ϯ 9 to 82 Ϯ 10 ml/min./100 g and 87 Ϯ 8 ml/min./ 100 g at 1 and 5 weeks, respectively (P Ͻ 0.01 and P Ͻ 0.05, Fig. 3C) . Maximum blood flow in the gastrocnemius muscle was even more drastically reduced from 176 Ϯ 9 to 39 Ϯ 5 ml/min./100 g 1 week after ligation and recovered slightly to 73 Ϯ 5 ml/min./100 g after 5 weeks (P Ͻ 0.001 for both conditions, Fig. 3D ). These results prove that bilateral ligation of the femoral artery in the nude rat leads to a persistent blood flow reduction both in the thigh and calf muscles.
Controlled angiogenesis by purified VEGFexpressing myoblasts
The different myoblast populations were implanted in 12 defined sites in the quadriceps and medial hamstring muscles 1 week after ligation, as shown graphically in Figure 3A . Control rCD8 cells produced only background rVEGF levels (0. 5 
Fig. 2: FACS-purification yields a myoblast population expressing a defined rVEGF level. Control rICD8 cells (A), primary transduced rVICD8 myoblasts (B) and clones expressing moderate (C, clone 2) or high VEGF levels (D, clone 8) were implanted in the posterior auricularis muscle of SCID mice. Four weeks later, vascular morphology was analszed in tissue whole-mounts by lectin staining (brown) and myoblast engraftment was revealed by XGal staining (blue). Size bars ϭ 50 m. (E) Clone 2, producing 53.5 Ϯ 2.1 ng of rVEGF/10 6 cells/day, was chosen as the reference clone. Its range of fluorescence intensity (pink shade) was divided into eight equal parts, shown by the vertical lines on the logarithmic scale of the FACS plot, and the middle two octiles (25%) defined the sorting gate (red shade). (F) This gate (black segment bar) was applied to the heterogeneous rVICD8 population (red curve) to yield the purified population (blue curve). The reference clone (black curve) and the negative control cells (grey-tinted curve) are also shown.
observed exclusively around transduced fibres and no effect could be found outside of these areas, which is consistent with secreted VEGF remaining localized in tissue. The vasculature in ischemic muscle treated with control rCD8 cells (Fig. 4B ) was similar to that in non-ischemic, non-treated muscles (Fig. 4A) Figure 4F , Figure 6A , (Fig. 6F) . [4] [5] [6] [7] . Furthermore, VEGF expression must also be sustained for at least 4 weeks to allow proper maturation of the new vessels and shorter durations lead to vascular regression [9, 20] . On the other hand, vessels that have not regressed by 4 weeks have been shown to persist for at least several months and even more than a year [9, 10, 20] .
VLD was significantly greater in animals treated with the VEGF-expressing myoblasts compared to control rCD8 cells or to non-ischemic muscle (P Ͻ 0.05 for all comparisons). These results show that controlled VEGF expression from FACSpurified cells in a model of chronic hind limb ischemia induced normal angiogenesis as efficiently as a clonal population with homogeneous expression of a similar VEGF level, leading to a greater than 50% increase in VLD compared to normal muscle. Both populations completely avoided the formation of aberrant vessels that were induced by the primary unsorted population.
Muscle blood flow after implantation of VEGF-expressing myoblasts
To assess whether the increased number of blood vessels in areas of engraftment of VEGF-expressing myoblasts was associated with a functional effect, maximum blood flow was measured in the thigh muscles, where cells had been injected, and further distally in the calf muscles 4 weeks after treatment, i.e. 5 weeks after femoral artery ligation. As shown in Figure 5, none of the populations of VEGF-expressing myoblasts significantly increased maximum blood flow in comparison to animals treated with BSA or control rCD8 cells, either in thigh or calf muscles.
Efficiency of engraftment of injected myoblasts
In order to investigate why the angiogenic induction observed by histological analysis was not accompanied by an increase in muscle blood flow, we examined the extent of stable engraftment of transduced myoblasts in the medial hamstring muscles 3 months after injection (n ϭ 4 per condition). As can be seen in
X-Gal ϩ muscle fibres could only be found along the needle tract of the intramuscular injections (white arrows). The engraftment pattern was similar for the control rCD8 cells, the reference clone, the primary rVICD8 population and the purified population (Fig. 6B-E, © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 Chronic hind limb ischemia model. (A) Schematic representation showing the location of femoral artery ligation and the 12 defined areas where myoblast populations were injected 1 week later (black dots) in the quadriceps and medial hamstring muscles. Maximum blood flow was measured in quadriceps (B), medial hamstring (C) and gastrocnemius (D) muscles 1 and 5 weeks after ischemia induction and in non-ligated animals. Values represent the mean Ϯ S.E.M. (n ϭ 10-12 per group
Discussion
VEGF is a fundamental regulator of angiogenesis both in development and disease and VEGF alone is capable of starting the complex cascade of events leading to the generation, growth and stabilization of new vessels [1], making it a very attractive candidate for the induction of therapeutic angiogenesis. However, direct gene therapy approaches have failed to establish a clear benefit in clinical trials, partly due to difficulties in establishing a therapeutic window for VEGF expression (reviewed in [2]). Prolonged expression of high VEGF levels is known to have toxic effects, such as uncontrolled vascular proliferation and the growth of angioma-like vascular tumours
We have previously found that, in order to avoid the growth of aberrant vessels, VEGF expression must be controlled in the microenvironment around each producing cell [9] 
Fig. 4 FACS-purified rVICD8 myoblasts induce normal, stable and mature angiogenesis in ischemic muscle. (A-E) The medial hamstring muscles were harvested 3 months after myoblast injection and frozen sections were immunostained with antibodies against endothelium (PECAM, in red), pericytes (NG2, in green) and smooth muscle cells (␣-SMA, in blue). Images were taken in areas where myoblast engraftment had been confirmed in adjacent serial sections stained with X-Gal. (A) nonischemic, non-treated muscle. (B) rICD8 control cells. (C) reference clone. (D) primary transduced rVICD8 population. (E) FACS-purified rVICD8 myoblasts. The white arrow in (D) indicates a large angioma-like aberrant structure. Size bars ϭ 50 7m. (F) Vessel length density (VLD) was measured around engrafted fibres and is expressed as the mean vessel length (in m) per fibre. Values represent the mean Ϯ S.E.M. (n ϭ 3-5). CD8: control cells
cell injections (white arrows). Higher magnification images showing similarly low engraftment rates with control cells (B), reference clone cells (C), the primary transduced population (D) and purified cells (E). Size bars ϭ 4 mm (A) and 400 m (B-E). (F) Engraftment was quantified on all XGal stained sections and expressed as a percent of the total muscle volume (n ϭ 3-5).
only about 10% of the donor myoblasts successfully engrafted in the recipient muscles [21] .
These [10] . The increased microcirculation may activate collateral growth through increased fluid shear stress, which has been shown to potently drive arteriogenesis through a nitric oxidedependent mechanism [23] .
It has been recognized that the complexity of growth factor dosing may be pivotal for the lack of efficacy in VEGF gene therapy clinical trials [24] and it has been advocated that preclinical development of vectors should include the routine analysis of 'STED' parameters: (i ) spread through the tissue; (ii ) transfection efficiency; (iii ) expression strength and (iv ) duration of expression [25] To induce chronic hind limb ischemia, we employed a previously described model of bilateral ligation of the femoral artery in the rat [16, 17] 
